FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Robert Ingalls Parker

Research Profile

Chemicals & Drugs

Anatomy

Living Beings

Infants

Concepts & Ideas

Disorders

Co-author Network

Publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Robert Ingalls Parker (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Robert Ingalls Parker
Coagulopathies in the PICU: DIC and liver disease.
Critical care clinics 2013;29(2):319-33.
2012: Robert Ingalls Parker
The big chill: cooling sickle cells with caution.
Critical care medicine 2012;40(2):703-4.
2011: Robert Ingalls Parker
Transfusion-related immunomodulation: how much of it is due to white cells?
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2011;12(5):593-4.
2011: Robert Ingalls Parker
Thromboprophylaxis in critically ill children: how should we define the "at risk" child?
Critical care medicine 2011;39(7):1846-7.
2011: Robert Ingalls Parker
Red blood cell transfusions in children: treat the child, not the number!
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2011;12(2):226-8.
2010: Parth Subhash Mehta; Robert Ingalls Parker
Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome.
Journal of pediatric hematology/oncology 2010;32(7):532-6.
2010: Robert Ingalls Parker; Margaret M Parker
Red cell transfusions and infections: not just for adults anymore.
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2010;11(4):524-5.
2010: Robert Ingalls Parker
Thrombosis in the pediatric population.
Critical care medicine 2010;38(2 Suppl):S71-5.
2010: Robert Ingalls Parker
Thrombosis in the intensive care unit: protein C and a whole lot more!
Critical care medicine 2010;38(2 Suppl):S1-2.
2009: Robert Ingalls Parker
Pediatric mast cell disease: what's the big (hematologic) deal?
Pediatric blood & cancer 2009;53(4):527-8.
2008: Robert Ingalls Parker
Platelets, von Willebrand factor, a disintegrin and metalloproteinase with thrombospondin motifs-13, plasma exchange and multiple organ failure: old problem, new approach.
Critical care medicine 2008;36(10):2955-6.
2008: Robert Ingalls Parker
Pediatric intensive care unit outcome following pediatric hematopoietic stem cell transplantation: quo vadis?
Critical care medicine 2008;36(10):2954-5.
2008: Robert Ingalls Parker
Who will care for tomorrow's children with benign hematologic conditions? A comment.
Pediatric blood & cancer 2008;50(5):1085; author reply 1086.
2007: Robert Ingalls Parker
Blood transfusions in patients with 22q11.2 deletion syndrome: assessment of risk requires identification of the at-risk patient.
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2007;8(5):502-3.
2007: Robert Ingalls Parker
Heparin-dependent platelet antibodies in children: problem or merely problematic?
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2007;8(4):404-5.
2007: Robert Ingalls Parker
Measurement of heparin-dependent platelet antibodies in the diagnosis of heparin-induced thrombocytopenia: fact or fiction?
Critical care medicine 2007;35(7):1784-5.
2006: Robert Ingalls Parker
Factor V Leiden and sepsis: Proof positive or phenomenology?
Critical care medicine 2006;34(8):2254-5.
2005: Robert Ingalls Parker
Recombinant activated factor VII: panacea or passing fad?
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2005;6(3):379-80.
2002: Keith G Ancona; Robert Ingalls Parker; Mark Atlas; Devina Prakash
Randomized trial of high-dose methylprednisolone versus intravenous immunoglobulin for the treatment of acute idiopathic thrombocytopenic purpura in children.
Journal of pediatric hematology/oncology 2002;24(7):540-4.
2002: Robert Ingalls Parker
Thrombocytopenia and intensive care unit outcome: a sticky issue.
Critical care medicine 2002;30(8):1917-8.
2001: Robert Ingalls Parker; D Prakash; R A Mahan; D M Giugliano; Mark Atlas
Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children.
Journal of pediatric hematology/oncology 2001;23(9):578-81.
2001: Robert Ingalls Parker
IIb/IIIa or not IIb/IIIa, that is adhesion.
Critical care medicine 2001;29(6):1286-7.
2000: Mushtaq A Godil; Mark Atlas; Robert Ingalls Parker; C J Priebe; M M Zerah; P Kane; J Tsung; Thomas A Wilson
Metastatic congenital adrenocortical carcinoma: a case report with tumor remission at 3 1/2 years.
The Journal of clinical endocrinology and metabolism 2000;85(11):3964-7.
2000: Robert Ingalls Parker
Hematologic aspects of systemic mastocytosis.
Hematology/oncology clinics of North America 2000;14(3):557-68.
1998: M M Parker; Robert Ingalls Parker
To sleep--perchance to dream: sedation of children for painful procedures.
Critical care medicine 1998;26(11):1791-2.
1998: Carolyn A Felix; MR Hosler; Diana J Slater; Robert Ingalls Parker; Margaret Masterson; James A Whitlock; TR Rebbeck; Peter C Nowell; Beverly J Lange
MLL genomic breakpoint distribution within the breakpoint cluster region in de novo leukemia in children.
Journal of pediatric hematology/oncology 1998;20(4):299-308.
1998: Robert Ingalls Parker; R S Siegel; M Z Ratajczak; A M Gewirtz
Deficient in vitro megakaryocytopoiesis and decreased in vivo platelet turnover in children and young adults with chronic thrombocytopenia.
Journal of pediatric hematology/oncology 1998;20(3):196-201.
1998: N Mahgoub; Robert Ingalls Parker; MR Hosler; P Close; Naomi J Winick; Margaret Masterson; Kevin Shannon; Carolyn A Felix
RAS mutations in pediatric leukemias with MLL gene rearrangements.
Genes, chromosomes & cancer 1998;21(3):270-5.
1997: R P Grewal; K T Yu; Norman W Barton; Robert Ingalls Parker; A M Bisceglie
Liver biopsies in patients with lysosomal storage disease: experience with effective sedation.
Indian journal of pediatrics 1997;64(6):887-91.
1997: Robert Ingalls Parker; HR Gralnick
Energy-dependent expression of platelet-von Willebrand factor on the surface of unstimulated and stimulated platelets.
The Journal of laboratory and clinical medicine 1997;130(5):520-9.
1997: Robert Ingalls Parker
Etiology and treatment of acquired coagulopathies in the critically ill adult and child.
Critical care clinics 1997;13(3):591-609.
1997: Robert Ingalls Parker; R A Mahan; D Giugliano; M M Parker
Efficacy and safety of intravenous midazolam and ketamine as sedation for therapeutic and diagnostic procedures in children.
Pediatrics 1997;99(3):427-31.
1995: O Alpan; Edmund LaGamma; Robert Ingalls Parker
Can treatment with recombinant granulocyte colony-stimulating factor transform neutropenia into leukemia?
The Journal of pediatrics 1995;127(5):845-6.
1994: Robert Ingalls Parker
Aggressive non-blood product support of Jehovah's Witnesses.
Critical care medicine 1994;22(3):381-2.
1993: Robert Ingalls Parker; G L Bray; L P McKeown; J G White
Failure to mobilize intracellular calcium in response to thrombin in a patient with familial thrombocytopathy characterized by macrothrombocytopenia and abnormal platelet membrane complexes.
The Journal of laboratory and clinical medicine 1993;122(4):441-9.
1993: Russell E Ware; Robert Ingalls Parker; L P McKeown; M L Graham
A human chimera for von Willebrand disease following bone marrow transplantation.
The American journal of pediatric hematology/oncology 1993;15(3):338-42.
1992: Robert Ingalls Parker; L P McKeown; John Gallin; HR Gralnick
Absence of the largest platelet-von Willebrand multimers in a patient with lactoferrin deficiency and a bleeding tendency.
Thrombosis and haemostasis 1992;67(3):320-4.
1992: Norman W Barton; Roscoe O Brady; James Dambrosia; S H Doppelt; Suvimol C Hill; C A Holder; Henry J Mankin; Gary J Murray; GC Zirzow; Robert Ingalls Parker
Dose-dependent responses to macrophage-targeted glucocerebrosidase in a child with Gaucher disease.
The Journal of pediatrics 1992;120(2 Pt 1):277-80.
1992: Robert Ingalls Parker; R P Grewal; L P McKeown; Norman W Barton
Effect of platelet count on the DDAVP-induced shortening of the bleeding time in thrombocytopenic Gaucher's patients.
The American journal of pediatric hematology/oncology 1992;14(1):39-43.
1991: T C Friedman; P M Thomas; T A Fleisher; Penelope Feuillan; Robert Ingalls Parker; Fernando Cassorla; George Chrousos
Frequent occurrence of asplenism and cholelithiasis in patients with autoimmune polyglandular disease type I.
The American journal of medicine 1991;91(6):625-30.
1991: Robert Ingalls Parker; Norman W Barton; Elizabeth J Read; Roscoe O Brady
Hematologic improvement in a patient with Gaucher disease on long-term enzyme replacement therapy: evidence for decreased splenic sequestration and improved red blood cell survival.
American journal of hematology 1991;38(2):130-7.
1991: HR Gralnick; SB Williams; L P McKeown; L Magruder; K Hansmann; M Vail; Robert Ingalls Parker
Platelet von Willebrand factor.
Mayo Clinic proceedings. Mayo Clinic 1991;66(6):634-40.
1991: Norman W Barton; Roscoe O Brady; James Dambrosia; A M Di Bisceglie; S H Doppelt; Suvimol C Hill; Henry J Mankin; Gary J Murray; Robert Ingalls Parker; C E Argoff
Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.
The New England journal of medicine 1991;324(21):1464-70.
1991: Robert Ingalls Parker
Hematologic aspects of mastocytosis: II: Management of hematologic disorders in association with systemic mast cell disease.
The Journal of investigative dermatology 1991;96(3 Suppl):52S-53S; discussion 53S-54S, 60S-65S.
1991: Robert Ingalls Parker
Hematologic aspects of mastocytosis: I: Bone marrow pathology in adult and pediatric systemic mast cell disease.
The Journal of investigative dermatology 1991;96(3 Suppl):47S-51S; discussion 50S, 60S-65S.
1990: Robert Ingalls Parker; P O'Shea; E N Forman
Acquired splenic atrophy in a sibship with the autoimmune polyendocrinopathy-candidiasis syndrome.
The Journal of pediatrics 1990;117(4):591-3.
1989: Robert Ingalls Parker; HR Gralnick
Effect of aspirin on platelet-von Willebrand factor surface expression on thrombin and ADP-stimulated platelets.
Blood 1989;74(6):2016-21.
1989: Robert Ingalls Parker; HR Gralnick
Inhibition of platelet-von Willebrand factor binding to platelets by adhesion site peptides.
Blood 1989;74(4):1226-30.
1989: B V Kettelhut; Robert Ingalls Parker; William D Travis; Dean D Metcalfe
Hematopathology of the bone marrow in pediatric cutaneous mastocytosis. A study of 17 patients.
American journal of clinical pathology 1989;91(5):558-62.
1989: William D Travis; G E Davis; Maria Tsokos; R Lebovics; H F Merrick; S P Miller; R E Gregg; A M Di Bisceglie; Robert Ingalls Parker; K G Ishak
Multifocal verruciform xanthoma of the upper aerodigestive tract in a child with a systemic lipid storage disease.
The American journal of surgical pathology 1989;13(4):309-16.
1989: T B Haddy; Robert Ingalls Parker; I T Magrath
Bone marrow involvement in young patients with non-Hodgkin's lymphoma: the importance of multiple bone marrow samples for accurate staging.
Medical and pediatric oncology 1989;17(5):418-23.
1988: Robert E Walker; Robert Ingalls Parker; Joseph A Kovacs; Henry Masur; H Clifford Lane; S Carleton; L E Kirk; H R Gralnick; Anthony Fauci
Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine.
Annals of internal medicine 1988;108(3):372-6.
1987: Robert Ingalls Parker; HR Gralnick
Fibrin monomer induces binding of endogenous platelet von Willebrand factor to the glycocalicin portion of platelet glycoprotein IB.
Blood 1987;70(5):1589-94.
1987: Robert Ingalls Parker; B C Shafer; HR Gralnick
Platelet density-dependent partition of platelet-von Willebrand factor between alpha granule and non-alpha granule pools.
Thrombosis and haemostasis 1987;58(3):911-4.
1986: Robert Ingalls Parker; H R Gralnick
Identification of platelet glycoprotein IIb/IIIa as the major binding site for released platelet-von Willebrand factor.
Blood 1986;68(3):732-6.
1986: HR Gralnick; M E Rick; L P McKeown; SB Williams; Robert Ingalls Parker; P Maisonneuve; C Jenneau; Y Sultan
Platelet von Willebrand factor: an important determinant of the bleeding time in type I von Willebrand's disease.
Blood 1986;68(1):58-61.
1986: Robert Ingalls Parker; E N Forman; K F Krumm; M J Abeel; H F Martin
Pharmacokinetics and toxicity of frequent intermediate dose methotrexate infusions.
Therapeutic drug monitoring 1986;8(4):393-9.
1985: Robert Ingalls Parker; M E Rick; HR Gralnick
Effect of calcium on the availability of platelet von Willebrand factor.
The Journal of laboratory and clinical medicine 1985;106(3):336-42.
1985: E J Seifter; Robert Ingalls Parker; H R Gralnick; M Wesley; V T DeVita; R C Young; Dan Longo
Abnormal coagulation results in patients with Hodgkin's disease.
The American journal of medicine 1985;78(6 Pt 1):942-50.
1984: Robert Ingalls Parker; M E Rick; HR Gralnick
A method to minimize platelet activation during platelet isolation.
Thrombosis research 1984;36(3):265-70.